18F-TFB PET Imaging for Thyroid Cancer
This trial is testing a new scan that can quickly show how much radioactive iodine thyroid cancer will absorb. It aims to help doctors plan treatment more effectively without interfering with the therapy. The study focuses on patients with thyroid cancer to improve their treatment outcomes.
Alkylating agents
Cyclophosphamide + Sirolimus for Advanced Thyroid Cancer
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Phosphodiesterase Inhibitor
Theophylline for Pseudohypoparathyroidism
This trial tests theophylline, a medication that helps important body signals last longer, in children and young adults with pseudohypoparathyroidism (PHP). These patients often struggle with obesity and short stature, which current treatments do not effectively address. Theophylline aims to improve their hormone response, potentially reducing weight and improving growth.
Popular Filters
Trials for Thyroid Cancer Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Trials for Thyroid Gland Carcinoma Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Trials for BRAF Positive Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Monoclonal Antibodies
Atezolizumab + Chemotherapy for Thyroid Cancer
This trial is testing a combination of atezolizumab and chemotherapy in patients with aggressive thyroid cancer. The treatment aims to boost the immune system and stop cancer cell growth. Atezolizumab helps enhance the immune response against cancer cells.
Kinase Inhibitor
Encorafenib + Binimetinib +/- Nivolumab for Thyroid Cancer
This trial studies how well encorafenib and binimetinib, with or without nivolumab, work in treating a specific type of thyroid cancer that has spread and doesn't respond to usual treatments. The drugs aim to stop cancer growth and help the immune system fight the cancer. Encorafenib and binimetinib are used in combination to treat BRAF V600 mutation-positive melanoma, showing improved response rates and survival.
Phase 3 Trials
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Vitamin D Analog
Paricalcitol for Secondary Hyperparathyroidism in Pediatric Kidney Disease
This trial is testing a medication called paricalcitol, which is taken by mouth, in young children with severe kidney disease and hormone imbalance. The goal is to see if it is safe and effective in balancing their hormone levels. Paricalcitol has been shown to be effective in reducing calcium and phosphorus levels in patients with kidney issues.
Trials With No Placebo
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
View More Related Trials
Frequently Asked Questions
Introduction to thyroid
What are the top hospitals conducting thyroid research?
When it comes to cutting-edge clinical trials focused on thyroid conditions, several top hospitals are making significant strides. One of these institutions is the Memorial Sloan Kettering Cancer Center located in New york City. With an impressive 14 active trials currently underway, this center is dedicated to advancing research and treatment options for patients with thyroid-related issues. Similarly, the M D Anderson Cancer Center in Houston stands out with 11 ongoing clinical trials specifically targeting thyroid disorders. Their commitment to exploring innovative approaches brings hope to those affected by thyroid conditions. Another prominent hospital contributing valuable insights is the Mayo Clinic in Rochester, which has a commendable eight active thyroid trials happening at present. This institution's dedication to improving patient care through scientific investigation makes them a leader in the field of thyrology.
The Ohio State University Comprehensive Cancer Center based in Columbus also plays a critical role in advancing our understanding of thyroid diseases through their five current clinical trials focusing on this area. By actively engaging in research and seeking breakthroughs, they aim to enhance treatment outcomes for individuals diagnosed with such conditions.
Even smaller-scale facilities like Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) located in Basking Ridge participate actively as well; despite having only four ongoing thyroid trials presently being conducted there, their contribution remains invaluable.
These esteemed hospitals collectively exemplify a commitment towards unravelling mysteries surrounding various aspects of thyrological complications that millions worldwide face every day.. Through collaborative efforts and unwavering determination, they strive toward discovering effective therapies that will ultimately improve lives and offer brighter futures for those impacted by these conditions
Which are the best cities for thyroid clinical trials?
When it comes to thyroid clinical trials, several cities in the United States lead the way in research and development. New york City boasts 27 active trials, exploring treatments like TransCon PTH, PET/CT Scan, and Vemurafenib. Houston, Texas follows closely behind with 22 ongoing studies focused on Pembrolizumab, pralsetinib (BLU-667), and Double-Blind Phase PLS240 among others. Boston, Massachusetts is also a hub for thyroid clinical trials with 19 active studies examining pralsetinib (BLU-667), Paricalcitol, Tirosint®-SOL, and more. Philadelphia and Rochester are additional key locations with significant ongoing research initiatives. These cities offer individuals dealing with thyroid conditions access to cutting-edge clinical trials that pave the way for advancements in treatment options and improve patient outcomes.
Which are the top treatments for thyroid being explored in clinical trials?
Clinical trials for thyroid treatments are underway, with several promising options currently being explored. Among the top contenders are:
- Lenvatinib: An active participant in multiple clinical trials, lenvatinib has shown potential as an effective treatment for thyroid conditions.
- Sorafenib: Another notable candidate, sorafenib is currently being investigated in various clinical studies focused on identifying its efficacy in treating thyroid-related ailments.
As researchers delve deeper into these clinical trials, they aim to uncover new and improved treatment options that can bring hope to individuals battling thyroid issues.
What are the most recent clinical trials for thyroid?
Recent clinical trials have explored new possibilities for the treatment of thyroid conditions. Among these studies is a Phase 2 trial investigating radioiodine-refractory, recurrent and/or metastatic differentiated thyroid cancer (DTC). Additionally, a Phase 3 trial is examining the efficacy of eneboparatide in patients with thyroid disorders. Another Phase 3 trial, known as Double-Blind Phase PLS240, focuses on evaluating a potential therapeutic option for individuals affected by thyroid-related issues. These ongoing trials offer hope for improved management and outcomes in patients with thyroid conditions.
What thyroid clinical trials were recently completed?
Recently, there have been several notable clinical trials focused on thyroid conditions that have reached completion. These trials aim to enhance our understanding and treatment options for thyroid-related disorders. One recent trial in particular investigated the potential benefits of a novel medication for treating hyperthyroidism. Another study examined the effectiveness of a targeted therapy for advanced thyroid cancer patients who had not responded well to standard treatments. These advancements signify important progress in the field and offer hope for individuals affected by thyroid disorders.